Company intelligence / Profile preview

AkiraBio

Wellesley, Massachusetts, United Statesakirabio.com ↗

Ownership: Private
Employees: ~2
Development stage: Other

Overview

AkiraBio develops molecularly targeted therapies using its proprietary Gene Programming™ platform to modulate gene expression at the DNA level. Its lead program targets DNMT1 and hemoglobin for treating sickle cell disease and related hematological conditions. The most advanced asset, NSC777586, is in preclinical development with a focus on increasing fetal hemoglobin levels to treat sickle cell disease and thalassemia. No published clinical results are available as of May 2025.

Therapeutic areas: HematologyOncology
Modalities: Chemical drugs (notably 2'-deoxycytidine analogs)Gene Programming™ platform
Industry: Biotech

Partnerships

Augusta University listed as originator organization for some assets/patents.

Beyond the preview

Go deeper on AkiraBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AkiraBio.